203. SURVIVAL IMPACT OF THORACIC DUCT RESECTION IN PATHOLOGICAL RESPONDERS AFTER TRIPLET CHEMOTHERAPY: EXPLORATORY ANALYSIS FROM MULTICENTER PHASE III TRIAL JCOG1109

Abstract Purpose JCOG1109 was a three-arm randomized phase III trial to confirm the survival advantage of docetaxel plus cisplatin 5-fluorouracil (DCF) and (CF) combined with radiotherapy (CF-RT) over CF as preoperative treatment for locally advanced esophageal squamous cell carcinoma. The purpose this study evaluate impact thoracic duct (TD) resection, its association pathological response in patients who were enrolled JCOG1109. Materials Methods: Patients potentially resectable cancer randomly assigned three therapies followed by open or thoracoscopic esophagectomy regional lymphadenectomy. Clinicopathological factors, surgical results which include status TD compared among groups. Furthermore, resection evaluated subgroup based on therapy. Results Between December 2012 July 2018, 601 (CF/DCF/CF-RT; 199/202/200). Of 589 eligible JCOG1109, 541 underwent (CF/DCF/CF-RT, 183/181/177). showed significantly worse PFS non-responders, whereas no significant difference responders. When analysis using response, better OS those received DCF achieved response. Conclusion Intensive local control might contribute improve responders after